Pfizer’s Vaccines Global Innovation Challenge: Winners announced


In line with its mission of ensuring that patients and medical centers worldwide have access to life saving vaccines, this Summer our gold sponsor Pfizer designed and launched a global challenge to seek for new and innovative approaches to educate patients on the importance of vaccines, mainly in adult and adolescent populations.

Pfizer was specifically looking for solutions aiming at:

  • ‌- Creating awareness of the importance as well as the risks and benefits of recommended vaccines, and delivering straightforward communication of vaccine recommendations
  • – Identifying locally/globally legal and regulatory-compliant ways for appropriate patients to access recommended vaccines.

To properly examine the numerous applications, Pfizer team adopted a highly selective evaluation process, assessing multiple features, among which: compliance, impact, market readiness, cost-effectiveness and scalability.

The selected companies have been invited to join a special Pitch Day event at FH21, where finalists had the chance to present their solutions in front of Pfizer Vaccines leadership team, interacting with the presenters in a compelling Q&A session.

The winning companies have just been announced:

Medorion

Telesofia Medical

Medorion implements a SaaS solution enabling healthcare organizations to create, manage, and measure highly personalized communication plans using best practices in Behavioral Science and helpful insights derived from clinical parameters in claims data.

Telesofia Medical proposes a platform allowing healthcare providers to automatically generate branded personalized educational videos for patients.

Both companies will benefit from mentorship and guidance from Pfizer experts and potential opportunities to collaborate on a market launch of the proposal in 2022 will be promptly explored.

Get a full access to the video on-demand from Frontiers Health 2021 Global Conference

MORE STORIES

IF YOU WOULD LIKE TO TAKE PART IN THE EVENT,
OR BE THE FIRST TO FIND OUT ABOUT OUR 2022 EDITION


MORE POSTS